Corporate Global Profile

AxoGen (NASDAQ: AXGN) is dedicated to the $2.2+ billion market for repair and protection of peripheral nerves; and is the leading company focused specifically on the science, development and, commercialization of technologies for peripheral nerve regeneration and repair. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their physical damage or discontinuity can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. AxoGen’s innovative approach to regenerative medicine has resulted in a comprehensive platform for nerve repair that offers benefits compared to traditional and competitive options. AxoGen's product portfolio includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive® Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal® Neurosensory & Motor Testing System and AxoTouch® Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other international countries.

- Processed nerve allograft for bridging transected peripheral nerves
- Available in lengths up to 70mm and diameters up to 5mm
- Proprietary process that maintains micro & macro structure to support axonal regeneration

- Bridges transected nerves up to 5mm
- Coaptation aid to facilitate tensionless repair
- Minimally processed ECM

- Wraps and protects injured nerves
- Reinforces coaptation sites
- Minimally processed ECM

- A minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed

- Measures, maps, and monitors nerve function in patients with peripheral nerve injuries
- Three accessory devices designed to evaluate neurosensory function and hand strength

INVESTOR FACT SHEET
As of December 31, 2017
Delivering Strong, Consistent Revenue Growth and Gross Margins
(U.S. $ in millions)

- Company focused on peripheral nerve repair and protection solutions
- U.S. market opportunity for peripheral nerve repair exceeds $2.2 billion
- Comprehensive platform for nerve repair
- Barriers to competitive entry and growing body of clinical data
- Strong growth with high gross margins
- Long term expansion potential beyond current markets

Strategic Initiatives
- Build Market Awareness
- Educate Surgeons, Develop Advocates
- Grow Body of Clinical Evidence
- Execute Sales Plan
- Expand product pipeline and applications

Company Leadership
Karen Zaderej
Chief Executive Officer
Peter J. Mariani
Chief Financial Officer
Greg Freitag
General Counsel & SVP Business Development
Jon S. Gingrich
Chief Commercial Officer
Shawn McCarrey
SVP Sales
Kevin Leach
VP Marketing
Mark Friedman, PhD
VP Regulatory Affairs & Quality Assurance
Erick DeVinney
VP Clinical & Translational Sciences
Mike Donovan
VP Operations
Dave Hansen
VP Finance & Treasurer
Ivica Ducic, M.D.
Medical Director

Contact
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
InvestorRelations@AxoGenInc.com
The Trout Group
Brian Korb, Investor Relations
646.378.2923
bkorb@troutgroup.com

Visit us at www.AxoGenInc.com